The Pharmacokinetic Properties and Bioequivalence of Methyldopa Formulations: Results of an Open-label, Randomized, Two-period, Crossover, Single-dose Study

Alexander Leonidovich Khokhlov^1,2, Leonid Nikolaevich Shitov^1,2, Miroslav Ryska³, Yuriy Aleksandrovich Dzhurko³, Vladimír Kube&scaron³, Vitaliy Nikolaevich Shabrov^1,2*, Aleksey Evgenyevich Miroshnikov¹, Elena Valeryevna Korneva⁴, Anna Vitalyevna Demchinskaya⁴, Anastasiya Mikhailovna Shitova^2,5, Igor Evgenyevich Shokhin¹ and Elena Georgievna Lileeva⁶

¹State Budget-funded Educational Establishment of Higher Professional Education “Yaroslavl, State Medical University” of the Ministry of Health of the Russian Federation,Yaroslavl, Russia

²Quinta-Analytica Yaroslavl LLC, Yaroslavl, Russia

³Quinta-Analytica s.r.o., Prague, Czech Republic

⁴R-Pharm JSC, Moscow, Russia

⁵State Educational Establishment of Higher Professional Education “Yaroslavl State University named after P. G. Demidov” of the Ministry of Education and Science of the Russian Federation, Yaroslavl, Russia

⁶Federal State Budget-funded Establishment of Science “Research Centre of Biomedical Technologies” of the Federal Medico-biological Agency of the Russian Federation, Svetlye Gory Village, Moscow Region, Russia

^*Corresponding Author: